Otilimab Failure Is A Blow For GSK’s Pipeline, With More Tests To Come

Arthritis Drug Was Blockbuster Candidate

 
• By Andrew McConaghie
GSK Stevenage
GSK is aiming to generate around $23bn in revenues from new products, but has had mixed results so far this year. • Source: GSK

More from Clinical Trials

More from R&D